Crinetics Pharmaceuticals EBIT 2017-2024 | CRNX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Crinetics Pharmaceuticals ebit from 2017 to 2024. Ebit can be defined as earnings before interest and taxes.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Crinetics Pharmaceuticals ebit from 2017 to 2024. Ebit can be defined as earnings before interest and taxes.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.4B
Zoetis (ZTS)	$70.5B
Takeda Pharmaceutical (TAK)	$44.1B
Daiichi Sankyo, - (DSNKY)	$43.3B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.5B
Astellas Pharma (ALPMY)	$17.5B
Summit Therapeutics (SMMT)	$17B
United Therapeutics (UTHR)	$16.4B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.6B
Orion OYJ (ORINY)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Corcept Therapeutics (CORT)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Ionis Pharmaceuticals (IONS)	$5.2B
Grifols, S.A (GRFS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.2B
Hypermarcas (HYPMY)	$2.2B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Dyne Therapeutics (DYN)	$1.4B
Ardelyx (ARDX)	$1.4B